tbuckley/cabot-search huggingface dataset:
Sialic Acid-Deficient Tumor Cells: Inhibition of Sialoglycoprotein Synthesis by Emetine2
Authors: Constance E. Brinckerhoff, Martin Lubin
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Sialic Acid-Deficient Tumor Cells: Inhibition of Sialoglycoprotein Synthesis by Emetine Get access Constance E. Brinckerhoff, Constance E. Brinckerhoff Search for other works by this author on: Oxford Academic PubMed Google Scholar Martin Lubin Martin Lubin Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 53, Issue 2, August 1974, Pages 567–572, https://doi.org/10.1093/jnci/53.2.567 Published: 01 August 1974 Article history Received: 05 March 1974 Accepted: 03 May 1974 Published: 01 August 1974
Abituzumab (Di17E6, Emd 525797) Treatment for Chemotherapy-Naive Patients with Asymptomatic or Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Primary Outcomes of the Placebo-Controlled Phase 2 Study Perseus (Nct01360840)
Authors: K. Miller, M. Hussain, S. Le Moulec, I. Rybicka, R. Bruns, J. Straub
Journal: Annals of Oncology (2014)
RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).
Authors: M. R. Gilbert, M. Wang, K. D. Aldape, R. Stupp, M. Hegi, K. A. Jaeckle, T. S. Armstrong, J. S. Wefel, M. Won, D. T. Blumenthal, A. Mahajan, C. J. Schultz, S. C. Erridge, P. D. Brown, A. Chakravarti, W. J. Curran, M. P. Mehta
Journal: Journal of Clinical Oncology (2011)

2006 Background: Radiotherapy with concomitant and adjuvant TMZ (TMZ/RT→TMZ) is the standard of care for newly diagnosed GBM. MGMT methylation status may be an important determinant of treatment response. Compared with the standard adjuvant TMZ, dd TMZ results in prolonged depletion of MGMT in blood mononuclear cells and possibly in tumor. This trial determined if intensified TMZ improves survival (OS) or progression free survival (PFS). Methods: This phase III trial was conducted by the RTOG, EORTC and NCCTG. Neurologically stable patients with adequate tissue for prospective MGMT analysis were randomized to Arm 1: standard TMZ (150-200 mg/m2 x 5 d) or Arm 2: dd TMZ (75-100 mg/m2 x 21 d) q 4 wks for 6-12 cycles. Symptom, QOL and neurocognitive testing was performed in a subset of patients. The primary endpoint was OS. Secondary analyses evaluated impact of MGMT status. Eligibility criteria included age > 18 yrs, KPS ≥ 60, and tissue block with > 1cm2 tumor. Results: A total of 833 patients were randomized from a total of 1173 registered. Inadequate tissue (n=144) and early disease progression (n =56) were the most frequent reasons for non-randomization. No statistical difference was observed between Arms 1 and 2 for median OS (16.6, 14.9 mo, p = 0.63), or median PFS (5.5, 6.7 mo, p = 0.06), or by methylation status. MGMT methylation was associated with improved OS (21.2, 14 mo, p < 0.0001), PFS (8.7, 5.7 mo, p < 0.0001) and response (p = 0.012). Cox modeling showed that MGMT status and RPA class were significant predictors of OS while the treatment arm and radiation technique (EORTC vs. RTOG) were not. There was increased grade ≥ 3 toxicity in Arm 2 (19%, 27%, p = 0.008); mostly lymphopenia and fatigue. Conclusions: This study did not demonstrate improved efficacy for dd TMZ for newly diagnosed GBM regardless of methylation status. However, it confirmed the prognostic significance of MGMT methylation in GBM. Additionally, it demonstrated the feasibility of tumor tissue collection, molecular stratification and collection of patient outcomes in a large transatlantic intergroup trial and established this as a viable clinical trial paradigm. Supported by NCI U10 CA 21661 and U10 CA37422.
Patients with primary membranous nephropathy are at high risk of cardiovascular events
Authors: Taewoo Lee, Vimal K. Derebail, Abhijit V. Kshirsagar, Yunro Chung, Jason P. Fine, Shannon Mahoney, Caroline J. Poulton, Sophia Lionaki, Susan L. Hogan, Ronald J. Falk, Daniel C. Cattran, Michelle Hladunewich, Heather N. Reich, Patrick H. Nachman
Journal: Kidney International (2016)
<sup>68</sup>Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma
Authors: Constantin Lapa, Katharina Lückerath, Irene Kleinlein, Camelia Maria Monoranu, Thomas Linsenmann, Almuth F. Kessler, Martina Rudelius, Saskia Kropf, Andreas K. Buck, Ralf-Ingo Ernestus, Hans-Jürgen Wester, Mario Löhr, Ken Herrmann
Journal: Theranostics (2016)

Chemokine receptor-4 (CXCR4) has been reported to be overexpressed in glioblastoma (GBM) and to be associated with poor survival. This study investigated the feasibility of non-invasive CXCR4-directed imaging with positron emission tomography/computed tomography (PET/CT) using the radiolabelled chemokine receptor ligand (68)Ga-Pentixafor. 15 patients with clinical suspicion on primary or recurrent glioblastoma (13 primary, 2 recurrent tumors) underwent (68)Ga-Pentixafor-PET/CT for assessment of CXCR4 expression prior to surgery. O-(2-(18)F-fluoroethyl)-L-tyrosine ((18)F-FET) PET/CT images were available in 11/15 cases and were compared visually and semi-quantitatively (SUVmax, SUVmean). Tumor-to-background ratios (TBR) were calculated for both PET probes. (68)Ga-Pentixafor-PET/CT results were also compared to histological CXCR4 expression on neuronavigated surgical samples. (68)Ga-Pentixafor-PET/CT was visually positive in 13/15 cases with SUVmean and SUVmax of 3.0±1.5 and 3.9±2.0 respectively. Respective values for (18)F-FET were 4.4±2.0 (SUVmean) and 5.3±2.3 (SUVmax). TBR for SUVmean and SUVmax were higher for (68)Ga-Pentixafor than for (18)F-FET (SUVmean 154.0±90.7 vs. 4.1±1.3; SUVmax 70.3±44.0 and 3.8±1.2, p<0.01), respectively. Histological analysis confirmed CXCR4 expression in tumor areas with high (68)Ga-Pentixafor uptake; regions of the same tumor without apparent (68)Ga-Pentixafor uptake showed no or low receptor expression. In this pilot study, (68)Ga-Pentixafor retention has been observed in the vast majority of glioblastoma lesions and served as readout for non-invasive determination of CXCR4 expression. Given the paramount importance of the CXCR4/SDF-1 axis in tumor biology, (68)Ga-Pentixafor-PET/CT might prove a useful tool for sensitive, non-invasive in-vivo quantification of CXCR4 as well as selection of patients who might benefit from CXCR4-directed therapy.
Liver Tumors and Contraceptive Steroids: Experience With the First One Hundred Registry Patients
Authors: W. M. Christopherson, E. Truman Mays
Journal: JNCI Journal of the National Cancer Institute (1977)

Because of reasonable evidence that contraceptive steroids are involved in the sudden increase of benign liver tumors in young women a registry of liver tumors was initiated at the University of Louisville in late 1973 to provide a source of  clinical and pathologic data and drug association. Patients with benign tumors varied in age from 14 to 47 years;  the average age was 29.8 years. The women tended to be long-term users;  the length of exposure ranged from 4 to 156 months.  Attempts to produce liver tumors in young female mice by feeding contraceptive steroids over many months have been unsuccessful.  The risk of liver tumors in users appears to be very small and should be evaluated in terms of the benefit of the medication.
Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).
Authors: D. A. Richards, J. J. Nemunaitis, S. J. Vukelja, C. T. Hagenstad, L. T. Campos, J. P. Letzer, R. C. Hermann, P. Sportelli, L. R. Gardner, J. C. Bendell
Journal: Journal of Clinical Oncology (2010)

3531 Background: Perifosine (P), a synthetic alkylphospholipid, inhibits or modifies signal transduction pathways including AKT, MAPK and JNK. We previously reported initial results of a phase II randomized study of P-CAP vs. CAP which demonstrated improved clinical activity of P-CAP over CAP in pts with mCRC. We now report the final safety, overall response rate (ORR), time to progression (TTP) and overall survival (OS) results. Methods: Pts with 2nd or 3rd line mCRC and no previous CAP in metastatic setting were randomized to P-CAP (P 50 mg PO QD + CAP 825 mg/m2 PO BID d1-14) or CAP (placebo + CAP 825 mg/m2 PO BID d 1-14). Cycles were 21 days. Results: 38 pts were randomized (20 P-CAP/18 CAP). Median age 67 (32-83); 61% male. Median prior Rx = 2 (1–5). Prior Rx of P-CAP arm vs. CAP arm: FOLFIRI (90% vs. 87%); FOLFOX (75% vs. 73%); bevacizumab (75% vs. 80%); EGFR antibody (45% vs. 60%); progressed on prior 5-FU-based Rx (70% vs. 73%). All 38 pts were evaluable for toxicity. Most frequent AEs (P-CAP vs. CAP): G3 /4: hand/foot syndrome (HFS) (30% vs. 0%), anemia (15% vs. 0%), fatigue (0% vs. 11%), bowel obstruction (0% vs. 11%); G1/2: diarrhea (65% vs. 28%), nausea (45% vs. 28%), fatigue (50% vs. 33%), HFS (25% vs. 22%). 35/38 pts were evaluable for response (3 CAP pts off study for AE). Results for P-CAP vs. CAP: ORR: 20% vs. 7%; Median TTP: 28 vs. 11 wks (p=0.012); and OS: 18 vs. 11 mos (p=0.0136). Subset analysis in pts with 5-FU refractory disease is shown in the Table. Conclusions: P-CAP is a well-tolerated regimen that has promising activity over CAP as 2nd or 3rd line therapy for pts with metastatic colorectal cancer. This improvement is consistent for the subset of pts with 5-FU refractory disease. A randomized phase III trial of P-CAP vs. CAP is planned for refractory colorectal cancer pts. Group 5-FU ref n (%) PR/SD Median TTP wks Median OS mos P-CAP 14 (70%) 1/8 18 [95% CI (12-36)] p=0.0004 15.3 [95% CI (8.4-26)] p=0.0088 CAP 11 (73%) 0/3 10 [95% CI (6.6-11)] 6.8 [95% CI (4.8-11.7)] Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Keryx Biopharmaceuticals Keryx Biopharmaceuticals Keryx Biopharmaceuticals
In Vivo Formation of &lt;italic&gt;N&lt;/italic&gt;-Nitrosomorpholine in CD-1 Mice Exposed by Inhalation to Nitrogen Dioxide and by Gavage to Morpholine&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: E W Van Stee, R A Sloane, J E Simmons, K D Brunnemann
Journal: JNCI Journal of the National Cancer Institute (1983)

Male CD-1 mice were exposed to approximately 20 ppm nitrogen dioxide (NO2 ) for 5–6 hours, to 1 g morpholine/kg body weight by gavage, or to both. Treatments were repeated daily for 5 consecutive days. N-nitrosomorpholine (NMOR) was found in whole carcasses (16–146 ng NMOR/mouse) in all animals that had been exposed to both NO2 and to morpholine, but NMOR was not found in tissues from animals that had been exposed to either chemical alone. Approximately one-third of the NMOR was found in the gastrointestinal tract, mainly in the stomach. The coadministration of 2 g sodium ascorbate/kg body weight or 1 g α-tocopheryl acetate/kg body weight had no effect on the amount of NMOR that was found in any tissue. Another possible product of the interaction of NO2 and morpholine, N-nitromorpholine, was not detected in any tissue. We concluded that the repeated, concurrent exposures of mice to NO2 by inhalation and to morpholine by gavage resulted in the in vivo formation of significant quantities of NMOR. The biological significance of the observation remains unknown.
Blood eosinophils as a marker of response to inhaled corticosteroids in COPD
Authors: Neil C. Barnes, Raj Sharma, Sally Lettis, Peter M.A. Calverley
Journal: European Respiratory Journal (2016)

Identification of a biomarker that predicts response to inhaled corticosteroids (ICS) would help evaluate the risk/benefit profile of ICS in chronic obstructive pulmonary disease (COPD) and guide treatment. The ISOLDE study randomised 751 patients (mean post-bronchodilator forced expiratory volume in 1 s (FEV 1 ) 1.4 L: 50% predicted normal) to fluticasone propionate 500 μg twice daily or placebo for 3 years, finding no difference in FEV 1 rate of decline between treatments (p=0.16) and a significant reduction in median exacerbation rate with fluticasone propionate versus placebo (p=0.026). We re-analysed ISOLDE results by baseline blood eosinophil count to investigate whether eosinophil level predicts ICS benefit. Patients with eosinophils &lt;2% (n=456) had a similar rate of post-bronchodilator FEV 1 decline with fluticasone propionate as placebo (–2.9 mL·year −1 ; p=0.688). With eosinophils ≥2% (n=214), the rate of decline decreased by 33.9 mL·year −1 with fluticasone propionate versus placebo (p=0.003). Exacerbation rate reduction on ICS for fluticasone propionate versus placebo was higher in the eosinophil &lt;2% group compared with the ≥2% group; time-to-first moderate/severe exacerbation was not different between treatments in either group. A baseline blood eosinophil count of ≥2% identifies a group of COPD patients with slower rates of decline in FEV 1 when treated with ICS: prospective testing of this hypothesis is now warranted.
Validation of four definitions of melancholia by the dexamethasone suppression test
Authors: J Davidson, S Lipper, W W Zung, R Strickland, R Krishnan, S Mahorney
Journal: American Journal of Psychiatry (1984)

The authors evaluated four sets of diagnostic criteria, the Newcastle Index, DSM-III, RDC, and the Michigan Diagnostic Index, for the diagnosis of melancholia. Forty-nine depressed inpatients, all of whom met RDC for major depression, also received consensus diagnostic assessment for melancholia. The dexamethasone suppression test (DST) was administered before drug treatment began. Results showed that the sensitivity of the DST ranged from 39% to 48%, specificity from 80% to 100%, and diagnostic confidence from 66% to 100%. All four scales received validation, but DSM-III showed the lowest specificity and predictive value.
Sexual and Reproductive Risk Factors for Invasive Squamous Cell Cervical Cancer
Authors: L A Brinton, R F Hamman, G R Huggins, H F Lehman, R S Levine, K Mallin, J F Fraumeni
Journal: JNCI Journal of the National Cancer Institute (1987)

Journal Article Sexual and Reproductive Risk Factors for Invasive Squamous Cell Cervical Cancer Get access Louise A. Brinton, Ph.D., Louise A. Brinton, Ph.D. 3 3Address reprint requests to Dr. Brinton, Landow Building, Room 3C06, National Institutes of Health, Bethesda, MD 20892. Search for other works by this author on: Oxford Academic PubMed Google Scholar Richard F. Hamman, M.D., Dr.P.H., Richard F. Hamman, M.D., Dr.P.H. Search for other works by this author on: Oxford Academic PubMed Google Scholar George R. Huggins, M.D., George R. Huggins, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Herman F. Lehman, D.D.S., Herman F. Lehman, D.D.S. Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert S. Levine, M.D., Robert S. Levine, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Katherine Mailin, Ph.D., Katherine Mailin, Ph.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Joseph F. Fraumeni, Jr., M.D. Joseph F. Fraumeni, Jr., M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 79, Issue 1, July 1987, Pages 23–30, https://doi.org/10.1093/jnci/79.1.23 Published: 01 July 1987 Article history Received: 27 May 1986 Revision received: 21 January 1987 Accepted: 09 February 1987 Published: 01 July 1987
Cutaneous Melanoma in Relation to Exogenous Hormones and Reproductive Factors&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: E A Holly, N S Weiss, J M Liff
Journal: JNCI Journal of the National Cancer Institute (1983)

Eighty-seven women of ages 37–74, who resided in King County, Wash., and who had been diagnosed between July 1976 and November 1979 as having cutaneous malignant melanoma, were interviewed regarding prior use of estrogen-containing preparations and reproductive history. The responses were compared with those of a random sample of 863 women from the same county. Among the 61 women with superficial spreading melanoma (SSM), use of oral contraceptives for 5 years or more was more common than among controls. The estimated relative risks for users of 5–9 and 10 years or more were 2.4 and 3.6, respectively. No differences between cases and controls were noted for oral contraceptive use of 4 years or less. Giving birth to a first child after age 30 was also associated with an increased relative risk of SSM. Although the positive findings regarding oral contraceptive use and age at birth of first child must be interpreted cautiously pending results of other studies, they suggest that hormonal factors can play a role in the etiology of SSM.
Phase I/II study of TH-302 in combination with gemcitabine in patients with solid tumors including advanced pancreatic cancer.
Authors: W. R. Schelman, M. J. Borad, E. G. Chiorean, A. C. Mita, G. Vlahovic, D. S. Mendelson, V. K. Langmuir, C. Eng, S. Kroll, J. C. Bendell
Journal: Journal of Clinical Oncology (2010)

e13519 Background: TH-302 is a 2-nitroimidazole hypoxia-activated prodrug of the DNA alkylator, bromo-isophosphoramide mustard. In preclinical models, TH-302 was active alone and enhanced the activity of gemcitabine (Gem). A phase I/II study was conducted to investigate TH-302 in combination with full dose Gem. Methods: This study used standard solid tumor eligibility criteria except patients (pts) must not have received prior Gem. Pts received IV TH-302 followed by Gem (1,000 mg/m2) on Days 1, 8 and 15 of a 28 day cycle. A standard 3+3 pts design was used with a TH-302 starting dose of 240 mg/m2. An expansion component was planned for first-line pancreatic cancer pts at the MTD. The objectives of the study were to determine the MTD/RP2D of TH-302 and Gem and to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of the combination. Results: 38 pts [20M/18F, median age: 62y (range 41-82), ECOG PS 0/1: 31/7] were enrolled at 8 sites and treated at TH-302 dose of 240 (7 pts), 340 (16), 400 (2), 480 (7) and 575 (6). Primary tumor sites: 18 pancreatic, 4 NSCLC, 3 bile duct, 3 ovarian, 2 neuroendocrine, 8 other. Treatment is ongoing in 11 pts; 24 pts discontinued prior to Cycle 6 (11 PD, 7 Pt/Physician decision, 3 clinical deterioration, 3 AE). Dose-limiting toxicities were grade 4 thrombocytopenia, grade 3 pain, fatigue, and esophagitis. Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 53%, 50% and 11% of pts. Skin and mucosal toxicities occurred in 26 (68%) and 17 (45%) pts; Gr 3 events were perineal rash, ankle ulcers and esophagitis. Other common AEs were nausea (65%), fatigue (63%), anorexia (40%) and vomiting (40%). The MTD was established at a TH-302 dose of 340 mg/m2 in combination with Gem at 1,000 mg/m2. There was no PK interaction between TH-302 and Gem. Best response included 11 PRs and 17 SDs were in the 35 evaluable patients, including 35% PRs and 59% SDs in 17 patients with first-line advanced pancreatic cancer. Conclusions: TH-302 may be administered in combination with full dose Gem. Hematologic toxicity was greater than with Gem alone. TH- 302-related skin and mucosal toxicities were dose limiting but reversible. Encouraging anti-tumor activity has been observed. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc.
Severe-glucose-6-phosphate dehydrogenase (G6PD) deficiency associated with chronic hemolytic anemia, granulocyte dysfunction, and increased susceptibility to infections: description of a new molecular variant (G6PD Barcelona)
Authors: JL Vives Corrons, E Feliu, MA Pujades, F Cardellach, C Rozman, A Carreras, JM Jou, MT Vallespi, FJ Zuazu
Journal: Blood (1982)
Randomized study to evaluate the efficacy of protease inhibitor(PI) in patients who underwent R0 resection of gastric cancer
Authors: H. Murakami, A. Tsuburaya, T. Yoshida, O. Kobayashi, M. Sairenji
Journal: Journal of Clinical Oncology (2004)

4264 Background: Among the metastases from gastric cancer, intra-abdominal metastases are dominant and peritoneum is the most frequent site of treatment failure. Protease is one of the mechanisms by which tumors cells disseminate and in various animal models, attenuation of metastasis by PI have been reported. We investigated the clinical effects of PI in patients who underwent R0 gastrectomy. Methods: From 1995 to 1996 patients with T2 or greater and M0 gastric cancer were preoperatively randomized to receive PIs, ulinastatin and camostat mesilate, which are broad spectrum protease inhibitors primarily used for pancreatitis, preoperatively (PIG) or not (CTR). Patients were stratified by the depth of the tumor (T2/ T3–4) and macroscopic type (type 1–3, 5/ type4). Ulinastatin was administered d.i.v. 10,000U/hr intraoperatively, 10,000U in the peritoneal cavity at closure, and 100,000U/day postoperatively for 4 days, followed by p.o. camostat mesilate for 4 weeks. Morbidity and survival were compared between the groups. 16 CTR patients 15 PIG patients were randomized and the patients were followed up for more than 5 years. Results: One patients in PIG was excluded because the tumor was unresectable and the rest of the patients were analyzed.Between CTR and PIG, duration of operation (118 min vs. 111 min), blood loss (340 ml vs. 375 ml), hospital stay (27 days vs. 23 days) were not different. No hospital death and PI-related morbidity were observed (elevation of AST/ALT in 1 CTR and 1 PIG, and cholecystitis in 1 CTR patients). Pathological findings were not different between the groups except for the depth of the tumor; more T3 tumor in CTR. 5(36%) patients in CTR recurred mainly in the peritoneum and 1(8%) in PIG recurred in the lung (p=0.1). 5-year survival for CTR and PIG were 56% and 71%, respectively (p=0.5). Conclusions: Perioperative PI was administered safely, however survival benefit was not apparent. Trend for less relapse for PI treated group may prompt further investigation in a large trial. No significant financial relationships to disclose.
A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria
Authors: Niamh O’Regan, Kristina Gegenbauer, Jamie M. O’Sullivan, Sanaz Maleki, Teresa M. Brophy, Niall Dalton, Alain Chion, Padraic G. Fallon, Georges E. Grau, Ulrich Budde, Owen P. Smith, Alister G. Craig, Roger J. S. Preston, James S. O’Donnell
Journal: Blood (2015)